Add Row
Add Element
Inner Momentum Media
update
Inner Momentum Media
update
Add Element
  • Home
  • Categories
    • Health
    • Mental
    • Trends
    • Nutrition
    • Weight
    • Work
    • Well Being
    • Finances
    • Fitness
    • Mindset
    • Pregnancy
    • Skincare
    • Extra News
    • Interviews with Experts
    • International Health News
    • New Research
Add Row
Add Element
June 03.2025
4 Minutes Read

Why UK Hospitals Must Implement Frailty Screening for Surgery Patients

Elderly patient in hospital bed for frailty screening, resting hand on rail.


Why Frailty Screening in Surgery Is Crucial for Older Patients

In an alarming revelation, a large-scale study has shown that nearly three-quarters of UK hospitals are missing a critical step in pre-surgical care: screening older patients for frailty. Conducted by the Royal College of Anaesthetists (RCoA) in conjunction with the University of Nottingham, this research reveals that 71% of hospitals do not routinely assess patients over 60 for frailty, despite the significant risks associated with this condition.

Frailty, which affects about 1 in 5 surgical patients aged over 60, drastically increases the likelihood of postoperative complications, extended hospital stays, and even mortality. The findings highlight a troubling trend in healthcare that could potentially hinder recovery for an increasingly aging surgical population. Acknowledging the seriousness of the situation is the first step towards improving patient care.

The Current Landscape: A Call for Action

The Sprint National Anaesthesia Project (SNAP3) data presents stark statistics: elderly patients suffering from frailty are three times more likely to suffer complications and four times more likely to experience postoperative delirium. To confront these alarming outcomes, researchers propose that frailty assessments should become a standard practice before surgery. This would not only enhance patient safety but fundamentally shift the approach to surgical care in the UK.

Dr. Claire Shannon, the president of the RCoA, voices the urgency for systematic frailty screening, stating that such measures could significantly streamline patient recovery and decrease unnecessary hospital stays. “As older individuals constitute an increasingly substantial part of the surgical demographic, effective frailty screening becomes imperative,” she asserts.

Understanding Frailty in Surgical Contexts

Frailty is not merely an age-related condition; it's a multifaceted concern that can stem from various health issues, influencing how patients respond to surgical procedures. According to the research, frail patients spend an average of three additional days in the hospital post-surgery, while severely frail individuals can face an extension of up to six days. This underscores an urgent need for increased clinician awareness and a more proactive approach in identifying vulnerable patients ahead of surgical interventions.

With evidence supporting the dire consequences of overlooking frailty, clinicians must be equipped with tools such as the Clinical Frailty Scale, enabling them to identify at-risk patients early on. This tool offers a straightforward assessment procedure that can lead to better patient preparation and engagement in post-operative care.

Collaborative Care: Key to Successful Outcomes

Collaboration among medical professionals is crucial in managing frail patients. Iain Moppett, chief investigator of SNAP3 and an esteemed professor, emphasizes that recognizing frailty must foster collaborative dialogues among surgeons, anaesthetists, and geriatricians. The goal is to enhance overall patient wellness pre-surgery and facilitate informed decision-making tailored to individual circumstances.

This approach advocates for forming cohesive teams committed to ensuring that frail patients receive the optimal support they need, allowing them to enter procedures in the best possible condition. The ripple effect of such improvements extends beyond individual patients to the healthcare system as a whole, optimizing resources and reducing pressure on hospital staff.

Transitioning Toward Better Patient Outcomes

The collective impact of these insights calls for a cultural shift in how surgical care is approached, particularly for older patients. By emphasizing frailty screening and promoting interdisciplinary collaboration, the healthcare system can mitigate risks and enhance outcomes for susceptible populations. As aware and informed as we must be, this proactive approach can pave the way for improved standards of care across the board.

Enhancing Patient Independence and Well-Being

Beyond the immediate surgical context, understanding frailty and its implications is key to enhancing overall patient independence and well-being. With an expanding demographic of older adults, the healthcare strategy must evolve to meet their unique needs.

By instituting routine frailty assessments, hospitals can not only ensure immediate safety but also contribute to long-term well-being, allowing individuals to maintain greater autonomy in their later years. As awareness grows and practices evolve, patients can expect more informed, compassionate, and comprehensive care.

Conclusion: The Path Forward

For older patients, the necessity of frailty screening cannot be overstated. As we glean insights from the SNAP3 study, it becomes clearer that implementing universal frailty assessments is essential for optimally caring for surgical patients. As trends in health care continue to evolve, prioritizing these assessments will not only enhance recovery results but also foster a culture of wellness and vigilance within the medical community.

Now is the time to advocate for change within the surgical framework for older patients. Be proactive in discussing frailty assessments with healthcare providers, utilizing tools and techniques that can significantly improve outcomes. When it comes to health and wellness, taking that first step could be transformative.


International Health News

0 Views

0 Comments

Write A Comment

*
*
Related Posts All Posts
06.05.2025

Unlocking Hope: CAR T-Cell Therapy Dramatically Improves PFS in Advanced Gastric Cancer

CAR T-Cell Therapy: A Breakthrough for Advanced Gastric CancerA new phase 2 clinical trial has revealed that satricabtagene autoleucel (satri-cel), a type of CAR T-cell therapy, significantly boosts progression-free survival (PFS) in patients suffering from advanced gastric and gastroesophageal junction cancers. These patients, who tested positive for the Claudin-18 isoform 2 (CLDN18.2) protein indicating aggressive malignancy, previously had limited treatment options, often facing grim prognoses.The Study: Methodology and Key FindingsThis randomized controlled trial, conducted across various centers in China, involved 156 participants with pathologically confirmed CLDN18.2-positive advanced diseases that had resisted multiple standard treatments. Participants received either the cutting-edge satri-cel therapy or treatment of physician's choice (TPC), which consisted of several conventional chemotherapy agents.The results were promising: patients receiving satri-cel had a median PFS of 3.25 months compared to just 1.77 months for those in the TPC group. Additionally, the objective response rate was markedly higher in the satri-cel group, achieving 22% versus only 4% in the control group. The data illustrated an impressive 63% reduction in the risk for disease progression or death.Understanding CAR T-Cell TherapyCAR T-cell therapy is a novel treatment method where a patient's immune cells are engineered to better recognize and attack cancer cells. For patients with advanced gastric cancers, where traditional therapies often fail, this innovative approach offers new hope. Satri-cel specifically targets the CLDN18.2 protein, found to be overexpressed in gastric malignancies. The treatment showcases a shift towards personalized medicine, where therapies are tailored based on the unique characteristics of a patient’s cancer.Life After Diagnosis: The Human ImpactThe emotional strain of being diagnosed with advanced cancer can be overwhelming, often leaving patients and families grappling with fears of mortality and questions about quality of life. The advent of effective treatments like satri-cel can transform this narrative, offering not just longer survival but also improved quality of life. Many patients share anecdotes of renewed hope and vitality after receiving innovative treatments that finally started working where others have failed.Looking Ahead: What’s Next for CAR T-Cell Therapy?While the results of the clinical trial are promising, researchers caution that further validation is essential. Future studies will focus on long-term outcomes to determine the efficacy and safety of satri-cel beyond initial treatments. Additionally, this research lays the groundwork for potential adaptations of CAR T-cell therapies to target other cancers, broadening the scope of this transformative technology.The Future of Treatment OptionsIn light of these advancements, it’s crucial for patients to stay informed about emerging therapies and advocate for themselves within the healthcare system. The innovative nature of CAR T-cell therapy may soon expand, leading to customized treatments that work better for various individual patients based on their unique cancer profiles.Final Thoughts: Embracing New Innovations in Cancer CareFor those navigating the often difficult landscape of cancer treatment, breakthroughs like satri-cel signify a beacon of hope. The ongoing advancements in medical research not only look to improve survival rates but also enhance the overall well-being of patients facing advanced cancers. Keeping abreast of these developments can empower individuals to make informed choices and remain hopeful about the future of their health.

05.30.2025

NICE Approves Sparsentan: A New Hope for Kidney Disease Patients

NICE's Groundbreaking Decision on SparsentanIn a pivotal turn of events for patients suffering from primary immunoglobulin A nephropathy (IgAN), the National Institute for Health and Care Excellence (NICE) has approved sparsentan (Filspari, Vifor Pharma) for treatment. This recommendation marks a reversal from their February decision, which denied NHS funding for the drug due to a lack of demonstrable value for money, highlighting a notable evolution in the assessment of newer treatments within the UK's healthcare framework.The Path to Approval: Evidence and ValueNICE's positive recommendation follows the manufacturer’s submission of additional analyses and agreement to a price discount viable for NHS budgets. This strategic negotiation exemplifies a growing trend of pharmaceutical companies demonstrating flexibility to address cost concerns while aiming to deliver innovative treatment options. It reflects a broader impetus in medical trends where patient accessibility and affordability drive decisions in healthcare policy.Clinical Benefits of SparsentanThis new therapeutic option has shown remarkable effectiveness in reducing the urine protein-to-creatinine ratio (UPCR), a key marker for kidney damage. Clinical trial results suggest that sparsentan outperforms standard treatments, including irbesartan, in maintaining kidney function, making it an exciting option for those affected by IgAN. Such advancements signify a hopeful horizon for over 4,200 patients with chronic kidney disease in England.Understanding IgAN and Its ImpactIgAN is recognized as one of the predominant causes of chronic kidney disease, affecting over 18,000 individuals in England. The condition manifests when immunoglobulin A, an antibody, builds up in the kidneys, leading to inflammation and often severe complications. This widespread impact underscores the necessity for effective treatments like sparsentan that can significantly improve patients' quality of life.The Mechanism Behind Sparsentan's EfficacySparsentan operates on a dual-action mechanism by blocking receptors for both endothelin-1 and angiotensin II. These hormones are known to exacerbate kidney damage, and their inhibition leads to reduced proteinuria and a slowed progression of kidney damage. The PROTECT study, a phase 3 clinical trial, provided compelling evidence for the drug's effectiveness, showing a marked decline in proteinuria compared to treatments currently standard in IgAN care.Emerging Treatment ParadigmsThe findings from the PROTECT study indicate that through the long-term administration of sparsentan, patients may experience a notable decrease in protein levels in urine—about 40% lower when compared to those treated with irbesartan—while also benefiting from better preservation of kidney function. While long-term efficacy remains to be continually evaluated, this innovative approach speaks volumes about the dynamic shifts within kidney disease management.A Bright Future for PatientsThe approval of sparsentan not only serves as a medical breakthrough but also instills hope among patients and their families as they navigate the challenges posed by chronic kidney illness. As more options become available, the emphasis on personalized treatment plans will change the landscape of patient care, promoting wellness and longevity.As we celebrate this advancement, it's vital for healthcare professionals and patients alike to remain informed about new therapies that can drastically improve life quality. Embracing innovation in treatment options can lead to more empowered patient choices.The conversation around health and wellness continues to evolve, and as more breakthroughs occur in medical research, organizations must remain vigilant in their assessments while ensuring drugs are both accessible and affordable for the populations they serve.

05.22.2025

After Breast Cancer Diagnosis: Why Weight Gain Matters for Survival

The Impact of Weight Gain Post-Breast Cancer DiagnosisRecent studies reveal a growing concern among healthcare professionals regarding the effects of weight gain on breast cancer outcomes. According to a study presented by Dr. Sixten Harborg at the European Society for Medical Oncology’s Breast Cancer 2025, substantial weight gain after a breast cancer diagnosis significantly increases mortality risk, especially for women who are overweight or of healthy weight at the time of diagnosis.Understanding the FindingsThe study focused on a subset of 6,803 women with non-metastatic breast cancer from the Nurses’ Health Study. Researchers examined the correlation between post-diagnosis weight changes and breast cancer mortality. They classified weight changes into categories ranging from stable weight to major weight gain, determining that women with major weight gains (over 5%) faced a heightened risk (adjusted hazard ratio of 1.26) compared to those maintaining a stable weight.This risk was especially pronounced in women who were classified as having a healthy weight or who were overweight prior to their cancer diagnosis, with adjusted hazard ratios of 1.32 and 1.37, respectively. In contrast, women who were already obese at the point of diagnosis did not show an increased risk tied to post-diagnosis weight gain.Unpacking the StatisticsWith nearly 1,179 women having succumbed to breast cancer during the study's median follow-up period of 8.5 years, the implications of these findings cannot be understated. Weight management post-diagnosis emerges as a crucial factor in improving outcomes for a significant number of patients.Broader Implications of Weight and HealthDr. Hope Rugo, an expert from the University of California, pointed out that the only patients affected by post-diagnosis weight gain were those whose starting weights were classified as normal or overweight. This suggests a troubling nexus: women who already face a higher mortality rate from breast cancer—including those diagnosed at a healthy weight—are further jeopardized by weight gain. However, the key takeaway here isn't just the danger of gaining weight but the need for survival strategies.Exploring Potential InterventionsAmidst these concerns, initiatives like the BWEL trial, involving over 3,100 women with stages II-III breast cancer, offer promises. It focuses on the potential benefits of weight loss interventions for improving survivorship outcomes, emphasizing an actionable path for women grappling with the challenges of weight management post-diagnosis.A Call for Action: What This Means for PatientsAs researchers continue to delve into the repercussions of weight changes on breast cancer survival, patients and healthcare providers must prioritize weight management as part of a comprehensive treatment plan. Understanding that post-diagnosis weight gain can exacerbate existing risks provides both a burden and an avenue for empowerment. Women within the target demographics should consult with oncologists and nutritionists to craft personalized plans aimed at sustainable health outcomes.This study serves as a rallying call for all affected individuals to embrace effective lifestyle changes, aiding not only in improving health outcomes but also in fostering a sense of control over their journey.Final ThoughtsIn light of these developments, it’s critical that patients who have faced or are facing breast cancer engage in discussions about maintaining a healthy weight. The evidence is clear: weight management post-diagnosis is no longer a secondary concern but a fundamental part of survivorship strategies. Talk with your healthcare provider and explore possible options, including weight management programs known to assist cancer survivors.

Add Row
Add Element
cropper
update
Inner Momentum Media
cropper
update

We distinguish ourselves by providing articles for time-constrained individuals. Inner Momentum Media blends practical advice, expert insights, and easy to implement steps to take.

  • update
  • update
  • update
  • update
  • update
  • update
  • update
Add Element

Inner Momentum

  • Privacy Policy
  • Terms of Use
  • Advertise
  • Contact Us
  • Menu 5
  • Menu 6
Add Element

248 290 8777

AVAILABLE FROM 10AM - 7PM

Address

West Bloomfield, MI
 USA

Add Element

ABOUT US

We are focused on comprehensive health and wellness trends, including fitness, nutrition, and mental health.

Add Element

© 2025 CompanyName All Rights Reserved. Address . Contact Us . Terms of Service . Privacy Policy

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*